Year-over-year earnings per share growth for the last twelve months: azitrainc.com (AZTR)

Symbol and logo of brand Azitra, Inc. (AZTR)

The Azitra, Inc. (AZTR) biotech sector is insulated from inflation and GDP fluctuations, demonstrating high resilience to crises. The quarterly EPS history visualizes this stability, where 86.20 shows the current value of the metric. Azitra, Inc. (AZTR) strives for leadership in treating rare skin pathologies, leveraging the synergy between geneticists and microbiologists to create innovative therapies.

Azitra Inc (AZTR) - Quarterly EPS earnings growth from 02/21/2024 to 11/12/2026

Summary analytical data breakdowns for Azitra Corporation (AZTR)

- share price and expert price forecast:
Stock Price Azitra|AZTR - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Azitra Corp|AZTR - Business Value
- book capitalization data:
Book Value per Share Azitra|AZTR - Book Capitalization|Market Cap to Net Assets Ratio azitrainc.com|AZTR - Total Asset Value of Company
- debt and solvency information:
Total Debt to Capital Azitra, Inc.|AZTR - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Azitra, Inc.|AZTR - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Azitra Corp|AZTR - Company Long-Term Loans and Borrowings|Company Short-Term Debts Azitra|Quick Liquidity Indicator azitrainc.com
- earnings and valuation multiples indicators:
AZTR - Final Profit|Projected Future Earnings Azitra, Inc.|AZTR - Business Payback Period|Future Price to Earnings Azitra Corp|AZTR - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Azitra Corp|AZTR - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Azitra|AZTR - Net earnings per share for the last four quarters|Quarterly EPS earnings growth azitrainc.com|AZTR - Earnings growth in current year|Expected earnings per share growth for next year Azitra, Inc.
Fundamental company valuation:Azitra, Inc.
Flagship merchandise of azitrainc.com

Investors must eliminate hidden risks by analyzing earnings per share (EPS) trends to assess the actual viability of the business model. By evaluating quarterly EPS progress, one can determine the extent to which modified skin microbe developments are capable of generating value amid market shocks, as this indicator measures net income growth rates, revealing operational efficiency imbalances and confirming the long-term financial stability of Azitra, Inc. (AZTR).

Who Azitra, Inc. competes with

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics Inc|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel Inc.)|Quarterly EPS earnings growth ORKA|Quarterly EPS earnings growth sanaramedtech.com (SMTI)|DBV Technologies - Year-over-year net earnings per share growth for the last 12 months|SLSN (Solesence Beauty) - Year-over-year net earnings per share trend for the last twelve months|Journey Medical Corp. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Forte Biosciences Inc FBRX|EMPG (Empro Group Inc) - Year-over-year net earnings per share growth for the last 12 months|SLGL: Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months AXIL Brands Inc|MDCX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth VRCA|Quarterly EPS earnings growth hoththerapeutics.com (HOTH)|Biofrontera - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months VYNE|Sonoma Pharma - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Quoin Pharmaceuticals QNRX|Dermata (DRMA) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months ELAB|RVNC (Revance Therapeutics) - Quarterly EPS earnings growth